Amiodarone-Avoid the danger of Torsade de Pointes

Resuscitation

Volumn 76, Issue 1, 2008, Pages 137-141

  Foley, Paul ^a   Kalra, Paul ^b   Andrews, Neil ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Amiodarone; Cholestyramine; Elimination; Torsade de Pointes; Ventricular arrhythmics

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CARBONATE; CHLORPHENIRAMINE; COLESTYRAMINE; FUROSEMIDE; INDAPAMIDE; INSULIN ASPART; ISOPHANE INSULIN; LEVOTHYROXINE; MACROGOL 3350; PAROXETINE; RAMIPRIL; THYROXINE; ZOPICLONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEFIBRILLATOR; DIAGNOSTIC IMAGING; DIZZINESS; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMAGE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QT INTERVAL; SYMPTOM; SYNCOPE; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; FEMALE; HUMANS; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES;

EID: 37149027276     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2007.07.011     Document Type: Article

References (20)

1. Kaski J.C., Girotti L.A., Messuti H., Rutitzky B., and Rosenbaum M.B. Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64 2 (1981) 273-279
2. Rosenbaum M.B., Chiale P.A., Kaski J.C., and Elizari M.V. Is amiodarone an ideal antiarrhythmic drug?. Pacing Clin Electrophysiol 7 2 (1984) 272-275
3. Hohnloser S.H., Klingenheben T., and Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121 7 (1994) 529-535
4. Letsas K.P., Filippatos G.S., Kounas S.P., Efremidis M., Sideris A., and Kardaras F. QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone. Cardiology 105 3 (2006) 146-147
5. Brown M.A., Smith W.M., Lubbe W.F., and Norris R.M. Amiodarone-induced torsades de pointes. Eur Heart J 7 3 (1986) 234-239
6. Tong K.L., Lau Y.S., and Teo W.S. A case series of drug-induced long QT syndrome and Torsade de Pointes. Singapore Med J 42 12 (2001) 566-570
7. Letsas K.P., Alexanian I.P., Pappas L.K., Kounas S.P., Efremidis M., Sideris A., et al. QT interval prolongation and torsade de pointes associated with indapamide. Int J Cardiol 112 3 (2006) 373-374
8. Lu Y., Yue L., Wang Z., and Nattel S. Effects of the diuretic agent indapamide on Na+, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ Res 83 2 (1998) 158-166
9. Wang C.P., and Guo G.B. Indapamide induced syncope in a patient with long QT syndrome. Pacing Clin Electrophysiol 25 9 (2002) 1397-1399
10. Guzzini F., Baroffio R., Coppetti D., and Gasparini P. Severe ventricular arrhythmia secondary to indapamide-induced hypopotassemia. Clin Ter 135 4 (1990) 283-287
11. Forfar J.C., and Gribbin B. Torsade de pointes after amiodarone withdrawal; effects of mild hypokalaemia on repolarization. Eur Heart J 5 6 (1984) 510-512
12. Committee M., Blomstrom-Lundqvist C., Scheinman M.M., Aliot E.M., Alpert J.S., Calkins H., et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in collaboration with NASPE-Heart Rhythm Society. Eur Heart J 24 20 (2003) 1857-1897
13. Da Costa A., Thevenin J., Roche F., Romeyer-Bouchard C., Abdellaoui L., Messier M., et al. Results From the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 114 16 (2006) 1676-1681
14. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
15. Soumerai S.B., McLaughlin T.J., Spiegelman D., Hertzmark E., Thibault G., and Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 277 2 (1997) 115-121
16. Yap Y.G., and Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 89 11 (2003) 1363-1372
17. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 10 (2004) 1013-1022
18. Pinski S.L., Eguia L.E., and Trohman R.G. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 25 11 (2002) 1612-1615
19. Nitsch J., and Luderitz B. Acceleration of amiodarone elimination by cholestyramine. Dtsch Med Wochenschr 111 33 (1986) 1241-1244
20. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 3 (2005) 225-237